BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 508
- Registration Number
- NCT01788358
Regulatory Post Marketing Surveillance Study in Korea
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2018-08-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3223
- Registration Number
- NCT01788722
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
- Conditions
- Hypertension, Pulmonary
- First Posted Date
- 2013-02-06
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Bayer
- Registration Number
- NCT01784562
Eylea Post Marketing Surveillance(PMS)
Completed
- Conditions
- Macular Degeneration
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3206
- Registration Number
- NCT01783925
- Locations
- 🇰🇷
Many Locations, Multiple Locations, Korea, Republic of
Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement
Phase 3
Completed
- Conditions
- Macular Edema
- Interventions
- Procedure: Macular Laser PhotocoagulationBiological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 381
- Registration Number
- NCT01783886
Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2017-12-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 17
- Registration Number
- NCT01781052
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
Phase 3
Completed
- Conditions
- Prevention & Control
- Interventions
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 27395
- Registration Number
- NCT01776424
Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A
Phase 3
Completed
- Conditions
- Hemophilia A
- Interventions
- Biological: BAY94-9027
- First Posted Date
- 2013-01-25
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 73
- Registration Number
- NCT01775618
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Phase 3
Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Drug: Regorafenib (Stivarga, BAY73-4506)Drug: Placebo
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 573
- Registration Number
- NCT01774344
Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy
Completed
- Conditions
- OphthalmologyMacular EdemaMacular Degeneration
- Interventions
- First Posted Date
- 2013-01-18
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 911
- Registration Number
- NCT01771081
© Copyright 2025. All Rights Reserved by MedPath